Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP) (OASIS)

NCT07823127 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07823127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07823127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP) (OASIS)
Lead sponsor
Mirum Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 15, 2027
Completion date
January 12, 2029
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholestasis of pregnancy